NCT05215470View on ClinicalTrials.gov

CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2026

Conditions
Renal Cancer Metastatic
Interventions
DRUG

Nivolumab

Nivolumab is called an anti-PD-1 (Programmed Cell Death Ligand 1) or a checkpoint inhibitor and is an antibody (a type of human protein) designed to allow the body's own immune system to destroy tumors

DRUG

Ipilimumab

Ipilimumab is called an anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) and is a type of antibody that works to prevent the body's immune system from stopping to fight a specific cancer

Trial Locations (1)

14040-900

Hospital das Clínicas da Faculdade de Medicina de Ribeirao Preto - USP, Ribeirão Preto

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Fundação de Amparo à Pesquisa do Estado de São Paulo

OTHER_GOV

lead

Hospital das Clínicas de Ribeirão Preto

OTHER

NCT05215470 - CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy | Biotech Hunter | Biotech Hunter